BATM Develops Molecular Diagnostics Test for Tuberculosis

BATM has developed a new method for the rapid and comprehensive diagnosis of tuberculosis (TB). The testing and validation phase, which is expected to commence in the second half of this year, will be fully funded under a program of the Stop TB Partnership, an international alliance comprising a wide range of governmental and non-governmental organizations.

The new method combines a one-step PCR test, developed by the Group's Adaltis subsidiary, with testing on the NATlab instrument using the new isothermal RCA process developed by the Group's Ador Diagnostics associate company. The PCR test diagnoses if someone is infected with TB and, if they test positive, the NATlab system is used to identify the strain of TB and its resistance to antibiotics (including rifampicin, isoniazid and quinolones). This process, which tests the same sample in both phases, is expected to produce results in approximately two hours, compared with several days for the current commonly used methods that often rely on incubation to determine antibiotic resistance after a patient has been diagnosed as infected with TB.

The Group presented this new method, which is being developed with the cooperation of a leading university in Italy, to the Stop TB Partnership at the end of 2019 and, following ongoing discussions, has now received the organization’s backing. The testing and validation of the solution will take place at the University of Heidelberg and will be fully funded under a program of the Stop TB Partnership.

Following the testing and validation phase, which is expected to begin in the second half of this year, the Group anticipates commencing sales of the new test next year.

"We are very excited about our new method for the diagnosis of TB and we are delighted to receive the support of the Stop TB Partnership and to work with the University of Heidelberg. We believe that our new method, which utilizes the advanced technologies of Adaltis and, in particular, the NATlab of Ador, will be particularly crucial in preventing the spread of drug-resistant TB strains. We also expect our solution to be more affordable and accessible than those used today,” Dr Zvi Marom, CEO of BATM, said. "The devastating health, social and economic consequences of TB have been with us for centuries and are still here today. It is vital that we develop innovative solutions and systems that will enable this disease, which is a leading cause of death but is both preventable and curable, to be eradicated. Thanks to the advances in molecular diagnostics, we are entering a new era in the fight against infectious diseases. I believe that BATM has an important role to play in this as we focus on developing new, innovative technologies while continuing to provide critical solutions to combat COVID-19."